Ms. Hsu primarily collaborates on projects in the area of colorectal cancer prevention involving the Adenoma Prevention with Celecoxib (APC) placebo-controlled clinical trial, with Dr. Zauber. She has worked on projects that explore the importance of genetic variants of NSAID metabolizing enzymes for dose-related anti-tumor response or toxicity related to celecoxib. She is currently involved with planned secondary analyses examining the use of statin drugs and other concomitant medications on the risk of adenoma recurrence.
Ms. Hsu also collaborates on numerous clinical projects with members of the department within the breast, lung, and gastrointestinal services, as well as within the department of radiation oncology. Ms. Hsu’s research interests include methods for survival analysis particularly for data with interval censoring, time-dependent and repeated measurements. She is also interested in the assessment of appropriate endpoints for clinical trials.